No Data
No Data
Galapagos Says Cancer Treatment Showed High Response Rate in Trial
By Ben Glickman Galapagos said its potential cancer treatment had shown high complete response rates in a clinical trial. The Belgian pharmaceutical company said Friday that GLPG5101, its T-cell can
Express News | Galapagos To Present Data On CD19 CAR-T Candidate GLPG5101 For Relapsed/Refractory Non-Hodgkin Lymphoma At EHA 2024
Galapagos Presents Encouraging New Data for CD19 CAR-T Candidate GLPG5101 in Non-Hodgkin Lymphoma at EHA 2024
Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV ((Euronext &, NASDAQ:GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate,
Retail Investors Are Galapagos NV's (AMS:GLPG) Biggest Owners and Were Hit After Market Cap Dropped €74m
Cystic Fibrosis Therapeutics Global Strategic Business Report 2023-2030 Featuring Key Players - AbbVie, Galapagos, Genentech, Gilead Sciences, Novartis, and Vertex Pharmaceuticals
Bruynzeel Wins Prestigious Order From Charles Darwin Foundation
PANNINGEN, Netherlands, June 13, 2024 /PRNewswire/ -- Bruynzeel Storage Systems, the leading provider of space-saving storage solutions in Europe, has secured a multi-million euro order from the Char
whqqq : Thank you for your comprehensive sharing